The case for & against
Bull & Bear analysis
Bearish
Synlogic, Inc. (NASDAQ: SYBX) is a clinical-stage biotechnology company specializing in synthetic biotic medicines aimed at treating metabolic diseases, particularly phenylketonuria (PKU) and enteric hyperoxaluria. With a focus on creating innovative, oral therapies utilizing its proprietary synthetic biology platform, Synlogic aims to address substantial unmet medical needs within these patient populations. The company holds a strategic position within the rare disease market, underscored by a challenging competitive landscape defined by limited effective therapeutic options.
Bull says
- ↑SYNB1618: 20% mean blood phenylalanine reduction in Phase II trial
- ↑$106.8M cash balance funds operations into 2024
- ↑EMA orphan‐drug designation for SYNB1618 supports expedited review
- ↑Over 75% of PKU patients untreated indicates large addressable market
- ↑Manufacturing capacity upgrades secure Phase 3 supply
- ↑High analyst revisions, robust profitability, low leverage and positive momentum
Bear says
- ↓Q2 net loss $15.7M vs revenue $0.2M raises viability concerns
- ↓FDA/regulatory delays may push trial readouts beyond expectations
- ↓Clinical trial enrollment hindered by COVID-linked labor shortages
- ↓Competition from BioMarin, Vertex, Amicus and emerging gene therapies
- ↓Low earnings yield, slow growth and small size risk limit appeal
- ↓Weak institutional ownership and moderate volatility may drive underperformance
Earnings Call · Q2 2021 · Mgmt. Guidance
Updated 07-10-2026neutral
Transcript signals
Bull points
- Under our current operating plan, we expect our cash and cash equivalents will be sufficient to fund the company through the second half of 2023. This will enable Synlogic to advance our clinical programs through important data readouts over the coming months.
- Under our current operating plan, we expect our cash and cash equivalents will be sufficient to fund the company through the second half of 2023. This will enable Synlogic to advance our clinical programs through important data readouts over the coming months.
- We're executing on our plans to demonstrate the clinical potential of our synthetic biotic platform in 2021.
Bear points
- the company reported a consolidated net loss of $14.5 million, or 28 cents per share, compared to a net loss of $15.5 million, or $0.44 per share for the corresponding period in 2020.
- Revenue was $0.2 million for the second quarter of 2021 compared to $0.4 million for the same period in 2020.
- the company reported a consolidated net loss of $14.5 million, or 28 cents per share, compared to a net loss of $15.5 million, or $0.44 per share for the corresponding period in 2020.
Read full transcript analysis ›